Shares of GSK plc (NYSE:GSK – Get Free Report) have earned a consensus rating of “Buy” from the eight ratings firms that are covering the stock, Marketbeat Ratings reports. Three analysts have rated the stock with a hold recommendation, two have issued a buy recommendation and three have given a strong buy recommendation to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $50.00.
Several research analysts have recently weighed in on GSK shares. Argus upgraded GSK to a “strong-buy” rating in a report on Wednesday, August 7th. Berenberg Bank raised GSK to a “strong-buy” rating in a research note on Thursday, June 20th. UBS Group downgraded GSK from a “buy” rating to a “neutral” rating in a research note on Monday, July 8th. Jefferies Financial Group lifted their price target on shares of GSK from $52.50 to $53.00 and gave the company a “buy” rating in a research report on Tuesday, July 2nd. Finally, The Goldman Sachs Group assumed coverage on GSK in a research note on Thursday, May 30th. They set a “neutral” rating and a $47.00 target price for the company.
Check Out Our Latest Analysis on GSK
Institutional Investors Weigh In On GSK
GSK Stock Performance
GSK opened at $41.29 on Friday. GSK has a twelve month low of $33.67 and a twelve month high of $45.92. The firm has a market capitalization of $85.57 billion, a PE ratio of 14.96, a PEG ratio of 1.32 and a beta of 0.64. The company has a current ratio of 0.82, a quick ratio of 0.58 and a debt-to-equity ratio of 0.99. The firm’s 50-day moving average price is $39.73 and its 200 day moving average price is $41.46.
GSK Increases Dividend
The business also recently announced a quarterly dividend, which will be paid on Thursday, October 10th. Investors of record on Friday, August 16th will be issued a $0.3843 dividend. This represents a $1.54 annualized dividend and a yield of 3.72%. The ex-dividend date is Friday, August 16th. This is an increase from GSK’s previous quarterly dividend of $0.38. GSK’s dividend payout ratio (DPR) is 54.71%.
About GSK
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
Read More
- Five stocks we like better than GSK
- What is a Low P/E Ratio and What Does it Tell Investors?
- JD.com Earnings Surprise: China’s Outlook Better Than Expected
- The How and Why of Investing in Gold Stocks
- Warren Buffett’s Recent Stock Moves: Top Buys and Sells to Watch
- Where to Find Earnings Call Transcripts
- Sea Limited’s E-Commerce and Fintech Strength Fuel Stock Surge
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.